Should You Buy Altimmune Inc (ALT) Today? Analysis, Price Targets, and 2026 Outlook.
Analysis Updated At
2026/01/29
Altimmune Inc (ALT) does not currently present a strong buy opportunity for a beginner investor with a long-term strategy. While the company has positive catalysts such as recent funding for its Phase 3 trial and a favorable analyst rating, its financial performance and recent stock dilution raise concerns. Additionally, technical indicators and trading signals do not suggest a strong entry point at this time.
Technical Analysis
The MACD is above 0 and positively contracting, indicating mild bullish momentum. RSI is neutral at 51.908, and moving averages are converging, suggesting no clear trend. Key support and resistance levels are at S1: 4.245 and R1: 6.086, with the stock currently trading near the pivot point of 5.166.
Analyst Ratings and Price Target Trends
Barclays initiated coverage with an Overweight rating and a $20 price target, highlighting undervaluation and strong fundamentals in the biotech sector. However, a prior analyst from Citizens JMP lowered the price target from $15 to $14, reflecting mixed sentiment.
Wall Street analysts forecast ALT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALT is 13 USD with a low forecast of 12 USD and a high forecast of 14 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Wall Street analysts forecast ALT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ALT is 13 USD with a low forecast of 12 USD and a high forecast of 14 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Current: 5.120
Current: 5.120
